News

• News

Ultragenyx raises $413M from two priority review voucher sales

pharminent October 15, 2026

• News

J&J raises 2026 guidance as Tremfya drives third-quarter immunology sales

pharminent October 14, 2026

• News

Roche licenses Rona’s RNAi obesity program in $1B deal

pharminent October 13, 2026

• News

FDA approves Asahi Kasei’s Hovilpri for refractory HSV lesions

pharminent October 12, 2026

• News

Viatris to acquire Pacira in $1.7B pain drug deal

pharminent October 9, 2026

• News

FDA approves Pfizer’s Tukysa combination for metastatic breast cancer

pharminent October 8, 2026

• News

AbbVie and Genmab’s Epkinly succeeds in frontline DLBCL trial

pharminent October 7, 2026

• News

Shionogi to acquire IntraBio for $2B in rare disease deal

pharminent October 6, 2026

• News

FDA approves Lilly’s Jaypirca for first-line CLL and SLL

pharminent October 5, 2026

• News

Novartis signs $7.8B Abogen deal for autoimmune T-cell engager

pharminent October 2, 2026

• News

Sanofi and Regeneron expand immunology alliance in $8B deal

pharminent October 1, 2026

• News

Novo to pay Hengrui up to $2.6B for once-weekly obesity pill

pharminent September 30, 2026

• News

AstraZeneca takes 10% Summit stake in $2B deal

pharminent September 29, 2026

• News

FDA approves AbbVie’s Parkinson’s disease therapy Juvmo

pharminent September 28, 2026

• News

FDA advisers back Grail’s multicancer detection blood test

pharminent September 25, 2026

• News

FDA approves Lilly’s once-weekly basal insulin Onswik for type 2 diabetes

pharminent September 24, 2026

• News

Amgen’s dazodalibep meets goals in phase 3 Sjögren’s trial

pharminent September 23, 2026

• News

FDA approves Lilly’s breast cancer combination treatment

pharminent September 22, 2026

• News

Telix to acquire ITM in deal worth up to $2.35B

pharminent September 21, 2026

• News

FDA approves Ultragenyx’s gene therapy Fayuvi for Sanfilippo syndrome type A

pharminent September 18, 2026

• News

NICE Clears Enhertu in HER2-Low Breast Cancer After England Raised Its Cost-Effectiveness Threshold

pharminent September 17, 2026

• News

Novartis Drops ALS for Lifonebart After Astrals Misses Every Endpoint — but Keeps the Molecule in Alzheimer’s

pharminent September 16, 2026

• News

GSK Licenses a Preclinical Trispecific T Cell Engager From China’s Chimagen for Up to $750M in Myeloma

pharminent September 15, 2026

• News

Scholar Rock’s Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning

pharminent September 14, 2026

• News

FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent

pharminent September 11, 2026

• News

Bayer’s Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer

pharminent September 10, 2026

• News

FDA Names Permanent CDER and CBER Directors While the Commissioner’s Post Awaits Confirmation

pharminent September 9, 2026

• News

Novartis’s Del-Desiran Misses Primary Endpoint in HARBOR, Putting the $12B Avidity Deal Under Scrutiny

pharminent September 8, 2026

• News

Novartis and Ionis’ Pelacarsen Lowers Lp(a) but Misses on Cardiovascular Outcomes

pharminent September 7, 2026

• News

Ionis Wins First-Ever FDA Approval for Alexander Disease with Zanvastro

pharminent September 4, 2026

• News

Ivonescimab Beats Keytruda on Survival in China-Only Trial as Its Global Study Stumbles

pharminent September 3, 2026

• News

UK Suspends Amgen’s Tavneos for New Patients as a Data-Integrity Cascade Spreads Across Three Regulators

pharminent September 2, 2026

• News

Novartis Posts Phase 3 MS Win and Halts Eight Autoimmune CAR-T Trials

pharminent September 1, 2026

• News

Lilly Pays Up to $2.875 Billion for Merida and a Phase 1 Autoantibody Platform

pharminent August 31, 2026

• News

FDA Approves Mounjaro Label Expansion to Reduce Cardiovascular Risk in Type 2 Diabetes

pharminent August 28, 2026

• News

FDA Approves Priovant’s LISRAYA (Brepocitinib), the First Targeted Therapy for Dermatomyositis

pharminent August 28, 2026

• News

FDA Approves Revolution Medicines’ Rasonque, First RAS(ON) Inhibitor for Metastatic Pancreatic Cancer

pharminent August 26, 2026

• News

FDA Approves J&J’s Imaavy for Warm Autoimmune Hemolytic Anemia, the First Therapy Ever Cleared in the Disease

pharminent August 25, 2026

• News

Genentech Licenses Hanmi’s Muscle-Sparing Obesity Drug in Deal Worth Up to $2.3 Billion

pharminent August 24, 2026

• News

Johnson & Johnson Wins EU Approval for Tecvayli-Daratumumab in Second-Line Myeloma

pharminent August 21, 2026